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G E N E T I C S
Myeloid Tribbles 1 induces early atherosclerosis via 
enhanced foam cell expansion
Jessica M. Johnston1, Adrienn Angyal1, Robert C. Bauer2,3, Stephen Hamby4, S. Kim Suvarna1, 
Kajus Baidžajevas1, Zoltan Hegedus5,6, T. Neil Dear7, Martin Turner8, The Cardiogenics 
Consortium*, Heather L. Wilson1, Alison H. Goodall4, Daniel J. Rader3, Carol C. Shoulders9†,  
Sheila E. Francis1, Endre Kiss-Toth1†
Macrophages drive atherosclerotic plaque progression and rupture; hence, attenuating their atherosclerosis- 
inducing properties holds promise for reducing coronary heart disease (CHD). Recent studies in mouse models 
have demonstrated that Tribbles 1 (Trib1) regulates macrophage phenotype and shows that Trib1 deficiency 
 increases plasma cholesterol and triglyceride levels, suggesting that reduced TRIB1 expression mediates the strong 
genetic association between the TRIB1 locus and increased CHD risk in man. However, we report here that 
 myeloid-specific Trib1 (mTrib1) deficiency reduces early atheroma formation and that mTrib1 transgene expression 
increases atherogenesis. Mechanistically, mTrib1 increased macrophage lipid accumulation and the expression of 
a critical receptor (OLR1), promoting oxidized low-density lipoprotein uptake and the formation of lipid-laden 
foam cells. As TRIB1 and OLR1 RNA levels were also strongly correlated in human macrophages, we suggest that a 
conserved, TRIB1-mediated mechanism drives foam cell formation in atherosclerotic plaque and that inhibiting 
mTRIB1 could be used therapeutically to reduce CHD.
INTRODUCTION
Atherosclerosis, a progressive disease of arterial blood vessels and 
the main underlying cause of stroke, myocardial infarction, and 
cardiac death (1), is initiated by the conversion of plaque macro-
phages to cholesterol-laden foam cells (2) in the arterial intima (3). In 
the early-stage atherosclerotic plaque, this transformation is induced 
by the uptake of both low density lipoprotein-cholesterol (LDL-C) 
and oxidized LDL (oxLDL) (2, 4), which may serve a beneficial 
purpose (3); but unrestrained, the crucial function of plaque macro-
phages in resolving local inflammation is compromised, and the 
development of unstable, advanced lesions ensues (3). It has been 
shown that foamy macrophages are not only less effective in clear-
ing apoptotic cells (5), they are also more prone to apoptosis (6), thus 
increasing secondary necrosis and the release of cellular compo-
nents and lipids that ultimately form the necrotic core of advanced 
plaques. Hence, there have been investigations into the identities of 
macrophage- specific proteins that induce lipid accumulation. Thus, 
myeloid– lipoprotein lipase (LPL), for example, has been shown to 
enhance the retention of LDL-C and triglyceride-rich remnant par-
ticles within the artery wall (7) and induce foam cell formation (8), 
while the scavenger receptor, oxidized low-density lipoprotein re-
ceptor 1 (OLR1) has been found to internalize oxLDL (9), promoting 
not only lipid accumulation and growth but also the survival of 
macrophage foam cells (10). Conversely, myeloid-ApoE expression 
has been shown to promote high-density lipoprotein (HDL)–mediated 
cholesterol efflux (11) and macrophage switching from a pro-
inflammatory (M1) to an alternatively (M2) activated phenotype 
(12). However, substantial advances in the development of cardio-
vascular disease (CVD) therapeutics await the identification of an 
apical regulator(s) that acts in a coordinated manner on the multiple 
downstream processes governing lipid accumulation, as well as 
atherogenicity of plaque- resident macrophages.
Tribbles 1 (Trib1) has been detected in murine plaque-resident 
macrophages (13), and variants at the TRIB1 locus have been associated 
with increased risk of hyperlipidemia and atherosclerotic disease in 
multiple populations (14, 15). However, no study had examined the 
macrophage-specific cellular processes dependent on myeloid-specific 
Trib1 (mTrib1) expression and how these tally with the assumed 
atheroprotective properties of this pseudokinase. At the whole-body 
level, one study has shown that Trib1-deficient mice have markedly 
reduced numbers of M2-like (F4/80+ MR+) macrophages in multiple 
organs, including adipose tissue (16). Hence, these studies strongly 
implicated that loss of macrophage-Trib1 expression within the arterial 
wall would lead to excessive atherosclerotic plaque inflammation 
and/or impair inflammation resolution and promote atheroma for-
mation. Moreover, in hepatocytes, Trib1 suppresses very-low-density 
lipoprotein production and de novo lipogenesis (15), indicating that 
the association between variants at the TRIB1 locus and atherosclerotic 
disease (14, 15) relates to loss of TRIB1 activity.
In the current study, we found that contrary to expectations, 
myeloid- specific knockout (KO) of Trib1 is atheroprotective, while 
mTrib1 expression is detrimental. In brief, Trib1 increased OLR1 RNA 
and protein expression, oxLDL uptake, foamy macrophage forma-
tion, and atherosclerotic burden in two distinct mouse models of 
human disease. The expression of these two genes, as well as those of 
LPL and SCARB1 (which mediates selective HDL-cholesterol uptake 
1Department of Infection, Immunity and Cardiovascular Disease, University of 
Sheffield, Beech Hill Road, Sheffield S10 2RX, UK. 2Division of Cardiology, Depart-
ment of Medicine, Columbia University Medical Center, New York, NY 10032, USA. 
3Perelman School of Medicine at the University of Pennsylvania and Children’s 
Hospital of Philadelphia, Philadelphia, PA 19104-5158, USA. 4Department of Cardio-
vascular Sciences, University of Leicester and NIHR Cardiovascular Biomedical 
Research Unit, Glenfield Hospital, Leicester, UK. 5Institute of Biophysics, Biological 
Research Centre, Hungarian Academy of Sciences, Temesvari korut 62, Szeged 
H-6726, Hungary. 6Departments of Biochemistry and Medical Chemistry, University 
of Pecs, Medical School, Szigeti ut 12, Pecs H-7624, Hungary. 7Division of Biomedical 
Services, University of Leicester, Leicester, UK. 8Laboratory of Lymphocyte Signalling 
and Development, The Babraham Institute, Babraham Research Campus, Cambridge 
CB22 3AT, UK. 9Centre for Endocrinology, William Harvey Research Institute, Queen 
Mary University of London and the Barts and the London School of Medicine and 
Dentistry, London EC1M 6BQ, UK.
*Membership of the Cardiogenics Consortium appears in the Supplementary Materials.
†Corresponding author. Email: c.shoulders@qmul.ac.uk (C.C.S.); e.kiss-toth@sheffield.
ac.uk (E.K.-T.)
Copyright © 2019 
The Authors, some 
rights reserved; 
exclusive licensee 
American Association 
for the Advancement 
of Science. No claim to 
original U.S. Government 
Works. Distributed 
under a Creative 
Commons Attribution 
License 4.0 (CC BY).
Johnston et al., Sci. Adv. 2019; 5 : eaax9183     30 October 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
2 of 14
(17)), is also tightly linked in human macrophages. Collectively, our 
studies reveal an unexpected beneficial effect for selectively silenc-
ing Trib1 in arterial plaque macrophages.
RESULTS
Myeloid Trib1 increases atherosclerosis burden
Immunostaining of human coronary atheromas from patients 
undergoing endarterectomies detected Trib1 in the arterial wall, 
including in 42.79 (± 2.31)% of CD68+ macrophages (Fig. 1A). We 
therefore examined the impact of macrophage Trib1 expression on 
atherogenesis by creating mice expressing low, wild-type (WT), and 
elevated levels of myeloid Trib1 as outlined in Fig. 1 (B to F). Although 
previous studies have demonstrated that global Trib1 KO significantly 
increases perinatal lethality (16), Trib1-floxed mice and myeloid- 
specific Trib1 KO (Trib1mKO) mice were fully viable and bred normally 
(fig. S1, A to D). mTrib1 transgenic (overexpressing, Trib1mTg) mice 
were also fully viable and bred normally. mTrib1 RNA levels were 
substantially lower in Trib1mKO than in floxed WT littermates, as 
judged by reverse transcription–quantitative polymerase chain 
reaction (RT-qPCR) assays performed on bone marrow–derived 
macrophages (BMDMs) prepared from these animals (Fig. 1G). As 
judged by enhanced green fluorescent protein (eGFP) expression, 
the bicistronic Trib1 transgene was expressed in 78.43 ± 2.33% and 
65.58 ± 0.92% of blood monocytes and peritoneal macrophages, 
respectively (Fig. 1G), and overall, the transgene increased BMDM 
Trib1 RNA levels by 2.49 ± 0.43 (SEM) fold (Fig. 1G, bottom right). 
Consistent with previous findings (18), the transgene was also ex-
pressed in neutrophils, which form a minor component of the immune 
cell population within very early-stage atherosclerotic lesions (19). 
Thus, we detected eGFP in 53.88 ± 2.41% and 34.93 ± 2.96% of 
Trib1mTg blood and bone marrow CD11b+/Ly6C−/Ly6G+ cells, 
respectively, compared to 25.95 ± 3.16% and 12.42 ± 2.01% in their 
CD11b+/Ly6C+/Ly6G− monocyte counterparts (fig. S1, E to I). 
However, in marked contrast to the reported full-body Trib1 KO 
mouse (16), Trib1mKO mice were not afflicted by reduced numbers 
of total, or individual, white blood cells (Fig. 1H) or by reduced 
macrophage numbers in their adipose tissue (F4/80+, fig. S2A), liver 
(F4/80+, fig. S2B), or spleen (F4/80+ and CD206+, fig. S2C). Similar 
to Trib1mKO mice, Trib1mTg mice displayed no gross abnormalities 
and had WT numbers of white blood cells (Fig. 1H). In addition, the 
sizes of their adipocytes (fig. S2A), liver (fig. S2B), and splenic (fig. 
S2C) macrophage populations were unaltered.
To address the contribution of mTrib1 in early atherosclerosis, 
we first transplanted bone marrow cells from the Trib1mKO and 
Trib1mTg mice and their respective controls (i.e., non-CRE, floxed 
KO, and Tg alleles) into 12- to 13-week-old lethally irradiated male 
ApoE−/− mice (Fig. 2A). Thus, all recipient mice received ApoE+/+– bone 
marrow cells to mitigate the previously described effects of total 
ablation of this apolipoprotein on both classical/proinflammatory 
(M1) and alternative/anti-inflammatory (M2) polarization (12) and 
to provide them with a physiologically important source of APOE 
to aid normalization of plasma cholesterol levels and of the lipoprotein 
profile in this otherwise extreme hyperlipidemic mouse model of 
human atherosclerosis (12, 20). In short, this experiment allowed 
modeling of early atherogenesis in a setting more akin to the human 
disease. Following a 7-week recovery period, the chimeric mice 
were fed a Western diet containing 0.2% cholesterol for 12 weeks. 
At sacrifice, and consistent with expectations of the study design, 
the chimeric mice had relatively low plasma cholesterol levels for a 
mouse model of human atherosclerosis (fig. S3A).
Unexpectedly, we found less atherosclerosis in the thoracic aorta of 
Trib1mKO➔ApoE−/− chimeras than in the control WT mice (Fig. 2B 
and fig. S4A). Conversely, there was a significantly higher atheroma 
burden in the Trib1mTg➔ApoE−/− mice (Fig. 2B and fig. S4A). Simi-
larly, the lesions in the aortic sinus were, on average, smaller in 
the Trib1mKO➔ApoE−/− mice and larger in the Trib1mTg➔ApoE−/− 
mice (Fig. 2C and fig. S4B). However, the collagen contents of the 
Trib1mKO➔ApoE−/− and Trib1mTg➔ApoE−/− in these “early-stage” 
plaques and their clinical pathology were comparable to those of the 
chimeric Trib1mWT➔ApoE−/− mice (fig. S4C). In short, we found 
that mTrib1 expression increased the atherosclerotic burden of 
ApoE−/− mice, despite having little impact on plasma LDL-cholesterol 
levels (fig. S3A).
To confirm that mTrib1 accelerates the development of athero-
sclerosis (Fig. 2, B and C), we created an LDL receptor (Ldlr) knock-
down model of human atherosclerosis (21) to induce hyperlipidemia 
and atherosclerosis in otherwise WT mice (21). Specifically, mice 
were injected with an adeno-associated virus (rAAV8) encoding for 
proprotein convertase subtilisin/kexin 9 (Fig. 2D), which previous 
studies have shown lowers both hepatic and extrahepatic surface 
cell expression of the Ldlr (22). Following feeding a Western diet for 
12 weeks, this intervention produced comparable, highly significant 
reductions in LDLR protein levels in the Trib1mTg and Trib1mWT 
mice (Fig. 2E) and a similar degree of hyperlipidemia (fig. S3B). 
However, despite this and consistent with mTrib1 expression in-
creasing atheroma formation in ApoE−/− mice, Trib1mTg injected 
with rAAV8-Pcsk9 developed a significantly higher atherosclerotic 
burden in their aorta and aortic sinus than their similarly injected 
Trib1mWT mice (Fig. 2, F and G).
Myeloid Trib1 increases macrophage/foam cell size 
in the atherosclerotic plaque
Next, we investigated the macrophage content and phenotype in 
the atherosclerotic plaque in each mouse model. This revealed that 
the aortic sinus lesions of Trib1mKO➔ApoE−/− mice contained a 
much smaller MAC-3+ immunoreactive area than the chimeric 
Trib1mWT➔ApoE−/− mice, while on average, the Trib1mTg➔ApoE−/− 
atheromas contained a marginally larger stained area (Fig. 3, A and B). 
However, there was no preferential loss of YM1+ macrophages in 
the Trib1mKO➔ApoE−/− lesions (Fig. 3B), consistent with the finding 
that M2 polarization of Trib1-deficient BMDMs isolated from whole- 
body Trib1mKO mice are compromised to a similar extent as M1 
polarization (23). In addition, we could not attribute the proatherogenic 
activity of myeloid Trib1 expression to a preferential increase in the 
proinflammatory macrophage (NOS2+) content of Trib1mTg➔ApoE−/− 
plaque (Fig. 3B, right). Rather, the increased atherosclerosis in the 
Trib1mTg➔ApoE−/− chimeras was attributable to a doubling of foam 
cell numbers (cells with characteristic foamy appearance and MAC-3+ 
(fig. S4D), and on average, these cells were also larger (Fig. 3, A and C, 
and fig. S4D). While the Trib1mWT-Pcsk9 atheromas had a similar- 
sized macrophage population (Fig. 3D), the size of the plaque-resident 
foam cells in the transgenic animals was larger (Fig. 3D).
In the Trib1mTg➔ApoE−/− chimeras, there was a stronger cor-
relation between the mean foam cell size and the percentage of aortic 
sinus stained by MAC-3 than between MAC-3+ staining and foam 
cell numbers (Fig. 3E), and we could not ascribe the observed increase 
in plaque-foam cell numbers on the effects of mTrib1 expression on 
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Fig. 1. Generation and characterization of myeloid-specific Trib1 mouse strains. (A) Representative immunohistochemistry image of human atherosclerotic 
plaque (P). Red, TRIB1; brown, CD68+. (ii) Magnification (×40) of boxed area. Arrowhead highlights a double-positive cell. Quantification (mean ± SD) of three patient 
samples. (iii) Isotype control (scale bar, 50 m). (B) Targeting construct used to produce the null, conditional-ready/floxed (tm1c) and conditional-null (tm1d) Trib1 
alleles. Predicted transcripts below. FRT, flippase recognition target; SA, splice acceptor; pA, polyadenylation motif; IRES, internal ribosome entry site; LacZ, 
-galactosidase; Neo, neomycin resistance gene. (C) Trib1mWT allele following removal of the “gene-trap” cassette. (D) Conditional-null Trib1 allele was produced by 
crossing tm1c and Cre-expressing mice. (E) Construct used to produce Trib1mWT and Trib1mTransgenic (Tg) mice. (F) Cre-mediated excision of the STOP cassette produces a 
bicistronic Trib1-eGFP transcript. Bent arrow, indicates transcription from endogenous Rosa26 promoter. (G) Trib1 RNA (relative to Actb) in BMDMs from homozygous 
tm1c (i.e., Trib1mWT) and Trib1mKO mice (n = 3 per group). eGFP expression in monocytes of three Trib1mTg mice and peritoneal macrophages from specified mice (n = 3 
per group). Trib1 RNA levels (relative to Trib1mWT) in BMDMs of Trib1mTg (n = 5 to 7 per group). (H) Blood cell counts of mixed-gender Trib1mKO (top) and Trib1mTg (bottom) 
and their respective WT littermates (n = 5 to 6 per group). Data are means ± SEM. Significances were determined by Student’s t test, *P < 0.05, **P < 0.01, and 
****P < 0.0001. ns, non-significant.
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blood cholesterol levels (Fig. 3E), HDL-C levels, or the nonsignificant 
rise in LDL-C (fig. S3). While the Trib1mWT➔ApoE−/− chimeras with 
the highest plasma cholesterol, HDL-C, and LDL-C concentrations 
had the lowest amount of MAC-3+ staining in their aortic sinus 
lesions, the inverse was true for the Trib1mTg➔ApoE−/− chimeras 
(Fig. 3E, right, and fig. S3). Thus, collectively, these data indicate 
that increased macrophage lipid uptake/storage was the prominent 
driving force for the observed foam cell expansion besetting the 
early stage of the atherosclerotic process in these and the Trib1mTg- 
Pcsk9 mice.
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chimeric mice with specified antibodies: MAC-3 (n = 9 to 12 per group) and double-positive YM1/MAC-3 (n = 7 to 14 per group) and NOS2/MAC-3 (n = 10 to 16 per group) 
cells. (C) Quantification of relative foam cell numbers (top) and size (bottom) in aortic sinus lesions of specified chimeras. n = 10 to 16 per group. (D) Representative images 
(scale bars, 30 m) of Elastic van Gieson– and MAC-3–stained aortic sinus lesions from specified mice injected with rAAV/mPCSK9 (n = 9 to 11 per group). Arrows in mag-
nified (×40) images of boxed area highlight foam cells. Quantification of MAC-3 staining and foam cell numbers and sizes (n = 6 to 7 per group). (E) Correlation between 
MAC-3 staining (x axis) in aortic sinus lesions of specified chimeric mice and foam cell numbers (left), foam cell size (middle), and plasma cholesterol levels (right). MAC-3 
staining expressed as percentage (%) of total aortic sinus lesion area. R2, Pearson correlation coefficient. In (B) to (D), data (means ± SEM) are expressed relative to WT. Sta-
tistical differences were determined by one-way ANOVA (B) or Student’s t test (C and D). *P < 0.05, **P < 0.01, and ***P < 0.001.
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Myeloid TRIB1 expression induces OLR1 expression in both 
mouse and man
To identify potential cellular mechanisms by which mTrib1 enhances 
foam cell expansion, we analyzed the gene expression characteristics 
of human TRIB1High monocytes and TRIB1High monocyte-derived 
macrophages (MDMs) using the microarray RNA data produced in 
the Cardiogenics Transcriptomic Study (CTS) (24). In this dataset, 
involving samples from 758 individuals, TRIB1 RNA levels were, on 
average, higher in monocytes than in MDMs (Fig. 4A, top) but, as is 
evident from the analyses of RNA levels in 596 paired samples, there 
was no correlation between TRIB1 RNA levels in these two cell 
types (Fig. 4A, bottom). Moreover, genes differentially expressed in 
TRIB1High versus TRIB1Low monocytes were enriched for different 
sets of “DAVID” Gene Ontology cluster terms (tables S1 and S2) 
than those characterizing the more lipid-based transcriptome of 
TRIB1High MDM (Fig. 4, B and C, and table S3).
The Cardiogenics Transcriptomic data strongly suggested that 
the mTRIB1-induced foam cell phenotype stemmed from increased 
oxLDL uptake rather than changes in LDLR and scavenger receptor 
class B type 1 [which mediates selective HDL-cholesterol uptake and 
efferocytosis (17)] expression (Fig. 4C) or reductions in ABCG1- 
and ABCA1-mediated cholesterol efflux (Fig. 4B). Notably, OLR1 
was the fourth most differentially expressed gene in the TRIB1High 
human MDMs and the most highly altered scavenger receptor in 
these cells (Fig. 4C). We therefore examined the effect of mTrib1 
transgene expression on the expression of this oxLDL receptor (9). 
This revealed that Trib1mTg BMDMs contained more Olr1 RNA but 
fewer Scarb1 transcripts (Fig. 4D) than their Trib1mWT counterparts, 
indicating that the increased numbers of OLR1 and reduced numbers 
of SCARB1 transcripts in human TRIB1High MDMs are causally re-
lated to the increased number of TRIB1 transcripts in these cells. 
The reciprocal relationship between OLR1 and SCARB1 RNA levels 
in TRIB1High MDMs was also recapitulated in interferon- (IFN-)/
lipopolysaccharide (LPS), interleukin-4 (IL-4)–polarized (fig. S5A) 
and fatty acid–polarized MDM samples but not in HDL-polarized 
MDMs (fig. S5B and table S4). Rather, HDL-polarized MDMs con-
tained OLR1 and SCARB1 RNA levels indistinguishable from those 
of nonpolarized MDMs (fig S5, A and B, and table S4), indicating 
that Trib1 induces Olr1 expression and foam cell formation via a non- 
HDL uptake–mediated mechanism. Last, to substantiate the evidence 
for causal TRIB1 involvement in OLR1 expression, we stained 
BMDMs for OLR1 protein. OLR1 was detected in twice as many 
Trib1mTg cells than their WT counterparts (Fig. 4E), consistent with 
the Western blotting analysis of whole BMDM cell lysates (Fig. 4F).
mTrib1-induced OLR1 expression in plaque macrophages 
increases atherosclerotic burden
To corroborate the evidence for causal mOLR1 involvement in plaque- 
resident macrophage foam cells expansion, we quantified OLR1 
expression in the aortic sinus lesions of our mouse models using an 
OLR1 antibody that recognizes the cell surface–expressed form of 
this oxLDL receptor, as well as the proteolytically cleaved (soluble) 
extracellular form (9). The antibody detected OLR1 in MAC-3+ cells 
and in acellular areas of the mouse aortic sinus lesions, including in 
regions adjacent to plaque macrophages (Fig. 5A). Moreover, as ex-
pected from the known expression and regulation of this scavenger 
receptor in endothelial cells (9), significant amounts of OLR1 was 
also detected in the nonmacrophage (i.e., MAC-3−) cell population 
at the plaque surface of the more hyperlipidemic model of human 
atherosclerosis (Fig. 5A and fig. S3). Last, confirming the causal in-
volvement of mTRIB1 in mOLR1 expression (Fig. 4, D to F), Fig. 5A 
shows that the anti-OLR1 antibody detected OLR1 in more of the 
plaque macrophages of Trib1mTg➔ApoE−/− mice than in those of 
the Trib1mWT➔ApoE−/− control animals (33.89 ± 6.56% versus 
16.18 ± 4.05%); a result which was replicated in the Trib1mTg-Pcsk9 
and Trib1mWT-Pcsk9 mice (29.35 ± 7.42% versus 10.38 ± 3.36%) 
(Fig. 5A).
To mechanistically validate the contribution of mTrib1-induced 
Olr1 expression to foam cell expansion, we incubated nonpolarized 
BMDMs with oxLDL for 24 hours. This led to marked rises in the intra-
cellular levels of both total cholesterol (2.71 ± 0.24–fold, P = 0.0091) 
and unesterified cholesterol (5.81 ± 0.83–fold, P = 0.0049) in the 
Trib1mTg BMDMs but not in their WT counterparts (Fig. 5B). In 
addition, as judged by Oil Red O staining, oxLDL transformed nearly 
three times as many Trib1mTg BMDMs into foam cells than Trib1mWT 
cells (P < 0.0001, Fig. 5C), as evidenced by the very visible increase 
in neutral lipid accumulation in these cells upon exposure to oxLDL. 
In contrast to the profound effects of oxLDL on cholesterol accu-
mulation in unpolarized Trib1mTg BMDMs, we observed no impair-
ment of HDL-mediated cholesterol efflux (Fig. 5D), consistent with 
the observation that neither Abca1 nor Abcg1 RNA levels are re-
duced in these BMDMs (Fig. 5D) and that the Trib1mTg➔ApoE−/− 
chimeras have higher, rather than lower, HDL-C levels than their 
WT peers (fig. S3). Thus, collectively, our results suggest that Trib1- 
induced foam cell expansion in early-stage atherosclerotic plaque 
arises from increased cholesterol/neutral lipid uptake and retention 
rather than reduced HDL-mediated cholesterol efflux.
DISCUSSION
Despite the success in establishing that hepatic Trib1 expression 
affects the regulation of multiple cellular processes modulating blood 
cholesterol and triglyceride levels (15), the influence of global-KO 
of Trib1 on shaping the phenotype of macrophages (16), and the 
finding that variants at the TRIB1 locus are associated with and in-
creased coronary heart disease (CHD) risk (14), the contribution of 
Trib1 on atherogenesis remains to be addressed. Here, we demon-
strate that there is a wide distribution of TRIB1 RNA levels in human 
MDMs and that genetically engineered changes in mTrib1 expression 
in mouse models of early-stage human atherosclerosis markedly 
affect the size of developing plaques and the morphological and 
functional properties of plaque macrophages (Fig. 6). In summary, 
we have confirmed the proatherogenic impact of myeloid TRIB1 in 
two distinct in vivo models of human atherosclerosis.
In the experiments reported here, we provide evidence that 
mTrib1 transgene expression may reduce vascular cell exposure to 
oxLDL given that it increased the size and lipid contents of plaque- 
resident foam cells in two independent models of early-stage ath-
erosclerosis by increasing mOLR1 expression and oxLDL uptake. 
Notably, in the less hyperlipidemic of these two transgenic models, 
we could also discern a very strong positive correlation between 
plaque macrophage numbers and plasma cholesterol/LDL-C levels, 
implying that in early-stage atherosclerosis, mTrib1High macrophages 
(in marked contrast to Trib1-deficient macrophages) are uniquely 
equipped to increase plaque macrophage numbers in response to 
lipid excess and hence foam cell and fatty streak formation.
Recent studies have established that oxLDL accumulates steadily in 
both early-stage (growing) and mature-stage (yellow plaque without 
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Fig. 4. Myeloid TRIB1 induces reciprocal changes in oxLDL and HDL receptor expression in human and mouse macrophages. (A) TRIB1 RNA levels in monocytes 
and MDMs of CTS participants (24). Correlation (R2 < 0.001, P = 0.47) was performed on 596 paired monocyte and MDM samples. (B) MDM (n = 596) and monocytes 
(n = 758) were ranked according to TRIB1 RNA contents and gene expression values in the top and bottom quartiles compared. Log2 fold changes (FC) of specified RNAs 
in TRIB1High (n = 149) versus TRIB1Low (n = 149) MDM, with associated P values. (C) FC and P values for differential expression of RNAs encoding representative scavenger 
receptors, including CD36, which mediates (ox)-phospholipid and long-chain fatty acid uptake (39), the acetylated-LDL scavenging receptor (40), and macrophage scavenger 
receptor (40). Comparisons are between TRIB1High versus TRIB1Low MDMs and between TRIB1High (n = 191) versus TRIB1Low (n = 191) monocytes. (D) RT-qPCR quantification 
of RNA (mean ± SEM) in BMDM prepared from specified mice (n = 5 to 9 per group). (E) Immunocytochemistry of nonpolarized Trib1mWT and Trib1mTg BMDMs. OLR1 (red), 
nuclei counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (blue). Scale bar, 50 m. Quantifications performed on BMDMs prepared from four to five mice per 
group. (F) Western blot analysis of OLR1 in Trib1mWT and Trib1mTg BMDMs (n = 3 to 5 per group). In (D) to (F), significance was determined by Student’s t test; *P < 0.05, 
and **P < 0.01.
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a necrotic core) human coronary plaques but that, in more advanced 
vulnerable plaques (yellow plaques with a necrotic core), this lipo-
protein is removed either by metabolism or replacement with other 
substances, including cell debris (2). These in vivo data dovetail well 
with the early in vitro work, which showed that while oxLDL pro-
motes macrophage growth and survival in a dose-dependent manner, 
beyond a certain lipid concentration, cell death ensues, albeit by an 
unknown mechanism (10). Thus, a critical question to consider 
is whether mTRIB1-induced OLR1 expression serves an (athero-) 
protective role in human atherosclerosis, for example, by reducing 
the exposure of plaque-resident vascular cells (where this disease is 
initiated) to oxLDL. This lipoprotein is a well-described activator of 
endothelial cell OLR1 expression with the totality of the data indi-
cating that this activation culminates in arterial endothelium dys-
function (9). That said, the endothelium is activated by numerous 
factors, including blood flow, hypertension, and inflammation (25), 
which over the life span of an individual may attenuate (and even 
erase) the potential atheroprotective effect arising from an mTRIB1- 
mediated reduction in the exposure of endothelial cells to oxLDL. 
By contrast, the effects of an mTRIB1-induced increase in OLR1 
expression will directly bear on atherosclerotic disease progression. 
Notably, it has been shown that mice overexpressing Olr1 on an 
ApoE KO background develop markedly more atherosclerosis than 
their nontransgenic littermates (26) and that Olr1 deficiency on an 
Ldlr KO background reduces the atherogenic burden conferred by 
18 weeks of a 4% cholesterol/10% cocoa butter diet (27). With spe-
cific reference to the macrophage component of atheromas, Schaeffer 
and colleagues (28) have shown that cytokine-induced up-regulation 
of OLR1 increased OxLDL internalization by >40%, suggesting 
that (in line with our data presented in fig. S5), in inflamed micro-
environments, where proinflammatory cytokines are relatively abun-
dant (such as in atherosclerotic lesions), increased OLR1 expression 
could play a substantial role in up-regulating oxLDL uptake and 
atheroma formation. Supporting this contention, we show here that 
the TRIB1-induced increase in OLR1 expression increased the 
uptake of oxLDL and lipid accumulation in plaque macrophages, 
which in vitro (10) and in vivo (9) studies have indicated, all other 
things being equal, will accelerate the formation of foam cells, foam 
cell apoptosis/necrosis, and the development of more advanced, 
complex lesions.
On the basis of the strong evidence of a causal link between 
hyper lipidemia and CHD (29) and the demonstration that ablating 
hepatic TRIB1 expression increased plasma levels of cholesterol, 
LDL-C, and triglyceride (15), the implication was,  which seemed 
to be entirely consistent with results from genome-wide association 
studies (GWAS) (14), that increasing TRIB1 would be atheroprotective. 
Silencing TRIB1 expression in macrophages, however, turns out to be 
atheroprotective, as judged by analyses of the aortas and aortic sinuses 
from Trib1mKO➔ApoE−/− chimeric mice, after a 12-week Western 
dietary regime. This counter intuitive result, which fits well with our 
in vitro and in vivo analysis of the consequences of mTrib1High expres-
sion on foam cell expansion, suggests moving forward that developing 
a therapy to specifically silence Trib1 expression in macrophages would 
provide clinical benefit beyond that of lipid-lowering medications, 
although full realization of this benefit may require its adoption at an 
early stage of atherogenesis. More generally, our study also demon-
strates that mechanistic probing of GWAS signals is not only warranted, 
but also critical, to identify both the totality and directionality of 
disease risk factors, even when, as was the case for TRIB1, the associ-
ation between a genetic variant(s), disease risk and a major disease- risk 
factor (plasma lipids) appeared congruent. Hence, we acknowledge 
that a limitation of the current study is that we have not addressed 
whether changes in vascular cell TRIB1 expression might affect 
Fig. 6. Model summarizing the proposed effects of differences in mTRIB1 
expression on foam cell expansion in early-stage atherosclerosis. Factors up- 
regulating mTRIB1 expression in human MDMs and plaque macrophages simulta-
neously increase cholesterol and neutral lipid uptake, with no compensatory rise in 
cholesterol efflux. Schematic recognizes that increased OLR1 expression increases 
the probability of this scavenger receptor assembling as a hexamer made up of 
three homodimers on the macrophage cell surface and that this configuration leads 
to a marked increase in its affinity for oxLDL (9) and hence OLR1-mediated uptake 
of oxLDL lipids. In the setting of no compensatory rise in HDL-mediated cholesterol 
efflux, accelerated foam cell expansion and increased atheroma burden ensue, 
highlighting the therapeutic potential of inhibiting macrophage Trib1 expression to 
block the gene expression changes that both promote macrophage cholesterol 
uptake and cholesteryl ester formation accumulation and prevent the increased 
hydrolysis of the accumulated cholesteryl ester and thus the up-regulation of the 
reverse cholesterol transport pathway to mediate the removal of cholesterol from 
the arterial wall.
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early-stage atherosclerosis development and whether the GWAS-CHD 
signal at the TRIB1 locus reflects that, in these cells (and hepatocytes), 
TRIB1 serves an atheroprotective role, in contrast to the situation in 
plaque-resident macrophages, where it induces foam cell expansion.
One of the most notable outcomes arising from roughly doubling 
Trib1 expression in macrophages was the increase in foam cell size 
that developed in both of our models of human atherosclerosis. Our 
results indicate that this was driven by the failure of these cells 
to increase HDL-mediated cholesterol efflux in response to an 
up-regulation of cholesterol and fatty acid uptake. In addition, this 
up-regulation was attributable to increased OLR1 RNA and protein 
expression, consistent with the in vitro studies of Lazar and co- 
workers (30), which demonstrated that Rosiglitazone induction of 
Olr1 expression in adipocytes increased oxLDL and palmitate uptake 
and cellular cholesterol levels. Likewise, when Steinbrecher and 
colleagues (28) increased macrophage OLR1 expression via lyso-
phosphatidylcholine stimulation, oxLDL uptake was also induced, 
prompting them to introduce the concept that macrophages within 
atheromas may be quiescent with respect to oxLDL uptake until 
Olr1 expression is induced (28). Here, we validate this concept by 
demonstrating overexpressing mTrib1 led directly to an increase in 
OLR1 protein in plaque-resident macrophages, alongside their in-
creased lipid contents and size. Our data also show that by doubling 
mTrib1 expression, we removed the requirement for an external 
stimulus to up-regulate OLR1 expression and the consequent clinical 
sequelae. The phenotype observed in response to this rise in mTrib1 
expression fits well with earlier computational modeling studies 
that indicated that relatively modest changes in TRIB1 would have 
a major impact on the activity of mitogen-activated protein kinase 
pathways; thus, defining the concentration of these proteins is critical 
for shaping cell function (31).
Thus, from the therapeutic standpoint, our results reveal that 
targeting TRIB1 expression could, in addition to beneficially affecting 
OLR1 expression, moderate CHD pathogenesis by simultaneously 
altering in favorable directions the expression of a number of other 
disease-promoting genes affected by changes in TRIB1 expression. 
These would include, for example, beneficially increasing NCEH1 
expression to reduce the release of proinflammatory cytokines from 
plaque-resident macrophages (32), while reducing the expression of 
LPL to help reduce the retention of LDL in the artery wall during 
early-stage atherosclerosis (7), as well as excessive accumulation of 
cholesteryl ester and triglycerides within macrophage foam cells (8). 
Whether mTRIB1 modulates atheroma regression (33, 34) and late-
stage atherosclerotic plaque stability by orchestrating a coordinated 
response to the lipid and inflammatory challenges encountered by 
plaque-resident macrophages/foam cells in advanced stage athero-
sclerosis now requires investigation.
MATERIALS AND METHODS
Human samples
Human tissue and blood samples were collected under protocols 
approved by the University of Sheffield Research Ethics Committee 
and Sheffield Teaching Hospitals Trust Review Board (ref. STH 
16346 and SMBRER310) and in accordance with the Declaration of 
Helsinki. All participants gave written informed consent. Human 
atheromas were from the left anterior descending artery of explanted 
hearts from three patients with ischemic heart disease undergoing 
cardiac transplantation. Patients were male and had a mean age of 
55.67 ± 2.51 (SD) years at the time of surgery. Lesions were classified 
as type V (American Heart Association). Specimens were fixed in 
10% (v/v) formalin and embedded in paraffin wax. Antigen retrieval 
was performed with trypsin for 15 min at room temperature (MP- 
955-K6, A. Menarini Diagnostics, UK). Sections were incubated with 
mouse anti-human CD68 (M0814, Clone KP1, Dako) antibody 
(1:100 dilution) and rabbit anti-human TRIB1 (09-126, Millipore, 
UK) antibody (1:100) and the appropriate secondary antibodies, 
biotin ylated horse anti-mouse secondary antibody and goat anti- 
rabbit secondary (BA-2000 and BA-1000, Vector Laboratories) 
anti body (both 1:200 dilution); and the detection reagents, Elite 
Mouse ABC horseradish peroxidase (HRP) (PK-6100, Vector Lab-
oratories), 3, 3′-diaminobenzidine (SIGMAFAST, D4293, Sigma- 
Aldrich), and rabbit ABC-Alkaline phosphatase and a Vector Red 
Alkaline phosphatase substrate kit (AK-5000 and SK-5100, Vector 
Laboratories). Sections were counterstained with hematoxylin and 
mounted with DPX mountant (44581, Sigma-Aldrich).
Mice and creation of murine models of myeloid-specific 
Trib1 expression
Mice were handled in accordance with U.K. legislation (1986) Animals 
(Scientific Procedures) Act. Mouse experiments were approved by 
the University of Sheffield Project Review Committee and carried 
out under a U.K. Home Office Project Licence (70/7992). All mice 
used were congenic on a C57BL/6J background (N17) and were 
housed in a controlled environment with a 12-hour light/dark cycle, 
at 22°C in Optimice® individually ventilated cages (Animal Care 
Systems) and given free access to a standard chow diet (2918; 
Harlan Teklad) and water. A knockout mouse project (KOMP) 
repository embryonic stem (ES) cell clone containing loxP sites flank-
ing exon 2 of Trib1 (EPD0099_ 5_D04) was used to generate a floxed 
Trib1 allele. The clone was geno typed to validate its authenticity, 
injected into C57BL/6J blastocysts, and transferred to pseudopregnant 
recipient females (Geneta). Resulting chimeras were mated with a 
flippase (FLP)–deleter strain maintained on a C57BL/6J background 
(Geneta), and floxed-Trib1 mice were generated. Trib1mKO mice were 
generated by crossing floxed mice with Lys2–cre recombinase trans-
genic mice (www.jax.org/strain/004781), excising all but the first 120 
amino acids of TRIB1. Murine Trib1 complementary DNA (cDNA) 
was introduced into the previously described pROSA26, loxP-flanked 
STOP and Frt-flanked internal ribosomal entry site–eGFP targeting 
construct (35) and then inserted into the ubiquitously expressed Rosa26 
locus of Bruce4 (C57/BL6J origin) mouse ES cells by homologous 
recombination. Correct integration was confirmed by Southern blot-
ting. Trib1mTg mice were generated by crossing floxed mice with the 
Lys2–cre recombinase transgenic mice described above. Mice were 
genotyped by PCR amplification of ear-clip samples. Trib1 fl/fl × 
Lyz2Cre and Rosa26.Trib1 × Lyz2Cre were genotyped for the presence 
of Lyz2Cre and for either Trib1 fl/fl or Rosa26.Trib1 using three primer 
sets (table S5). For the atherosclerosis experiments, mice were fed a 
Western (21% fat and 0.2% cholesterol) diet (829100; Special Diet 
Services, Braintree, UK) for 12 weeks.
mTrib1 RNA quantification
BMDMs were cultured for 5 days in complete medium: Dulbecco’s 
modified Eagle’s medium (DMEM) (BE12-604F, Lonza) containing 
10% (v/v) L929-conditioned medium, 10% (v/v) ultralow endotoxin 
fetal bovine serum (FBS) (S1860-500, Biowest, USA), and penicillin 
(100 U/ml) and streptomycin (100 ng/ml) (15140-122, Gibco). 
Total RNA was isolated using a ReliaPrep Kit (Z6011, Promega) 
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and reverse transcribed into cDNA using an iScript cDNA Synthesis 
Kit (1708890, Bio-Rad). Trib1 was quantified using the TaqMan 
assay Mm00454875, which amplifies a 99-nucleotide amplicon 
comprising exon 2 and 3 sequences.
myeloid-green fluorescent protein (mGFP) quantification
GFP-positive cells in freshly purified peripheral blood monocytes 
were isolated by positive selection using magnetic MicroBeads con-
jugated with F4/80 (130-110-443, Miltenyi Biotec) and CD115 
(130-096-354, Miltenyi Biotec) using a modified version of the pro-
tocol described by Houthuys et al. (36). Inflammation was induced 
by injecting phosphate-buffered saline (PBS) containing thio-
glycollate into the peritoneal cavity and isolating the infiltrating 
cells, as described (37). The percentages of GFP-positive cells in 
blood and bone marrow cells (from femurs and tibiae) were deter-
mined using mice euthanized humanely by cervical dislocation. Red 
blood cells (RBCs) were lysed using RBC lysis buffer (00-4300-54, 
eBioscience). Approximately 106 cells per sample were resuspended 
in PBS, and dead cells were removed using an amine-reactive dye, 
NIR Zombie (1:500 dilution in the antibody master mix; 423105, 
BioLegend). Live cells were stained with the following cell surface 
marker–specific antibodies, at 0.1 g/ml each in 100-l total volume: 
AF647-conjugated anti-human/mouse CD11b (101220, BioLegend), 
phycoerythrin (PE)–conjugated anti-mouse Ly6C (101220, BioLegend), 
and PE/Cy7-conjugated anti-mouse Ly6G (127617, BioLegend). 
Cells were sorted on an LSR II Cytometer (BD Bio science) equipped 
with 355-, 405-, 488-, and 633-nm excitation lasers. Quantifications 
were performed with FlowJo software.
Blood counts
Blood counts of heparinized blood, obtained via cardiac puncture, 
were determined using a Sysmex KX-21 N quantitative automated 
hematology analyzer.
Histological analysis
Adipose tissue and liver samples were paraffin-embedded. Cross 
sections were stained with hemotoxylin and eosin or incubated 
with F4/80 [1:50; 565409 (clone T45-2342), BD Pharmingen], fol-
lowed by biotinylated rabbit anti-rat antibody (1:200; Vector Labo-
ratories, UK) and PE-streptavidin (1:20; 405203, BioLegend). They 
were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) 
(P36931, Invitrogen) and mounted with ProLong Gold antifade 
mountant. Mean adipocyte sizes were determined using NIS- Elements 
software (Nikon Instruments, UK) by measuring at least 15 cells per 
field of view and three fields of view per mouse. Frozen spleen sec-
tions were stained with F4/80 [PE-rat anti-mouse 123019 (clone BM8, 
BioLegend)] or CD206− [Alexa Fluor 647 rat anti-mouse 321116 
(clone 15-2, BioLegend)]–conjugated antibodies (1:200), counter-
stained with DAPI, and mounted with Aqua- Mount (Thermo Fisher 
Scientific). Fluorescent images were captured using an inverted wide-
field fluorescence microscope (Leica AF6000).
Models of early-stage human atherosclerosis
For the bone marrow transplantation model, 12- to 13-week-old 
mixed-gender donor mice were euthanized humanely by cervical 
dislocation. Femur/tibae bone marrow cells were isolated and puri-
fied by standard methods and resuspended in Hank’s balanced salt 
solution (without phenol red, 14175053, Thermo Fisher Scientific) 
containing 10% (v/v) fetal calf serum. Donor cells (2 × 106 to 4 × 106) 
were transplanted via tail vein injection to randomly allocated 12- 
to 13-week-old male ApoE−/− recipient mice that were lethally irra-
diated with 11 grays (Gy) in two doses (5.5 Gy on two occasions 
separated by 4 hours) on the day of the transplantation. Bone mar-
row transplant experiments were undertaken in two waves, one for 
each mTrib1 model and respective WT control. During the 7-week 
posttransplant recovery period, the chimeras were fed a standard 
chow (2918; Harlan Teklad) diet and then switched to Western diet 
(21% fat and 0.2% cholesterol, 829100; Special Diet Services, Braintree, 
UK) for 12 weeks. Chimera mice were given sterile acidified drink-
ing water [1.1% (v/v) HCl] until the end of the procedure.
PCSK9 model
An adeno-associated virus-based vector (rAAV8) that supports 
transport of the mPCSK9D377Y gene to the liver was purchased from 
UNC GTC Vector Core (Chapel Hill, NC). The mice received 6.1 × 
1011 viral particles via a single tail vein injection. Following 7-day 
recovery, they were transferred to the Western diet (829100, Special 
Diet from Braintree, UK) for 12 weeks.
Lipid measurements
Fasting, plasma total cholesterol, HDL-C, triglycerides, and glucose 
levels were measured on a Roche Cobas 8000 modular analyzer. 
LDL-C was estimated by the Friedewald equation. In addition, col-
orimetric assays (Cholesterol Quantification Kit, MAK043, Sigma- 
Aldrich; Triglyceride Assay Kit, ab65336, Abcam) were used.
Atherosclerotic plaque assessment
Mice were perfused through the heart with PBS and then with 10% 
(w/v) neutral-buffered formalin. The aorta was segmented at the 
diaphragm and at the top of the aortic arch. Following careful re-
moval of surrounding extraneous fat and connective tissue, it was 
dissected longitudinally and fixed in 4% (w/v) paraformaldehyde. 
Dissected aortas were stained with Oil Red O [60% (v/v) in isopro-
panol] and pinned onto wax. Images were taken with a macroscopic 
charge-coupled device camera and analyzed by computer-assisted 
image analysis (NIS-Elements software, Nikon Instruments, UK). 
Aortic sinus samples were obtained by excising the heart and tran-
secting parallel to the atria. Following fixation in 10% formalin (v/v) 
buffered saline for at least 24 hours, samples were serially cut 
(at 7-m intervals) from the valve leaflets until the beginning of 
the aorta.
Immunohistochemistry
Aortic sinus sections were dewaxed and rehydrated. Heat-mediated 
antigen retrieval was performed with 10 mM sodium citrate and 
nonspecific staining reduced by incubation in 5% (v/v) goat serum 
(G9023, Sigma-Aldrich) for 30 min at room temperature. Primary 
antibodies diluted as appropriate were as follows: rat anti- mouse 
MAC-3 antibody clone M3/84 (1:100 dilution, BD Pharmingen), rabbit 
polyclonal NOS2 antibody (1:100; ab15323; Abcam, UK), rabbit 
anti-mouse YM1 polyclonal antibody (1:100; ab93034; Abcam, UK) 
and or rabbit polyclonal OLR1 (1:100; ab203246; Abcam, UK). 
The secondary antibodies were biotinylated rabbit anti- rat secondary 
antibody (1:200, Vector Laboratories BA-4000), goat anti-rat DyLight 
488 goat anti-rat DyLight 488 (GtxRt-003488NHSX, ImmunoReagents 
Inc.), and goat anti-rabbit DyLight 550 (GtxRb- 003-D550NHSX, 
ImmunoReagents Inc.). Rabbit anti-rat–conjugated biotinylated anti-
body was visualized with the Vectastain ABC-HRP complex (PK-
6100, Vector Laboratories). Sections were counterstained with 
Carazzi’s hematoxylin. The number and area of foam cells (MAC-3+ 
macrophages containing a vacuolated cytoplasm) were quantified us-
ing NIS-Elements software (Nikon, UK). Fluorescent images were 
captured using an inverted wide-field fluorescence microscope 
(Leica AF6000). Quantification of YM1, NOS2, and OLR1 in the 
Johnston et al., Sci. Adv. 2019; 5 : eaax9183     30 October 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
12 of 14
aortic sinus lesions was confined to macrophage (MAC-3+) cells 
only and analyzed using ImageJ.
Clinical grading
The atherosclerotic burden of the atheroma in aortic sinus samples 
was graded according to the Stary system (e.g., 1 = presence of 
macro phage foam cells, 2 = presence of intracellular lipid accumu-
lation, and 3 = presence of extracellular lipid pools) (38) using a 
light microscope (Zeiss Axiophot, Carl Zeiss, Jena, Germany) and 
Image Access. Slides were randomized, and the cardiac pathologist 
was fully blinded to sample origin.
Western blotting
Twenty micrograms of total protein lysates was size-fractionated on 
4 to 12% NuPAGE Bis-Tris Gel (NP0321, Invitrogen). OLR1 was 
detected by incubation with a rabbit anti-mouse OLR1 antibody 
(1:500, ab203246; Abcam), followed by HRP-conjugated goat anti- 
rabbit immunoglobulin G (IgG) (1:1000; P0448, Dako). LDLR was 
detected by incubation with a rabbit polyclonal antibody (1:1000; 
3839-100, BioVision, USA) at 4°C overnight followed by HRP- 
conjugated goat anti-rabbit IgG (1:1000; P0448, Dako). -Tubulin was 
used as a housekeeping control (sc-32293, Santa Cruz Biotechnology). 
Detection of immunoreactive products was performed using 1:1 
ECL reagent (RPN2235, GE Healthcare) and a C-DiGit Blot scanner 
(Model 3600, LI-COR). Densitometry was performed with Image 
Studio Lite software (LI-COR).
Gene expression studies
RNA from BMDM was prepared as described above. RT-qPCR was 
performed using primer sequences provided in table S5 and either 
SYBR-Green (PrecisionPLUS, Primer Design, UK) or a TaqMan 
(Invitrogen) assay (TRIB1, Hs00921832; OLR1 Hs01552593; SCARB1, 
Hs00969821, Thermo Fisher Scientific). Values were normalized to 
either Actb (Mm02619580, Invitrogen) for mouse samples or GAPDH 
for human samples (Hs02786624, Invitrogen). Fold changes were 
calculated using the Ct method.
Microarray analyses
Details of the CTS, which comprises transcriptomic data from iso-
lated monocytes from 758 donors and matched MDM samples 
from 596 donors, have been published (24). In brief, monocytes 
were isolated from whole blood using CD14 immunobeads and 
cultured for 7 days with macrophage colony-stimulating factor 
(MCS-F) to generate macrophages. The top and bottom quartiles of 
TRIB1-expressing samples were defined respectively as TRIB1High 
and TRIB1Low. Comparable sizes of differentially expressed gene 
lists (n = 1842 monocytes; n = 2171, MDM) were obtained by using 
false discovery rate (FDR)- adjusted P values (i.e., q values) of <0.01 
plus cutoff log2 fold changes of >0.071 (up-regulated) and >−0.071 
(down-regulated) for the MDM dataset. The Database for Annotation, 
Visualization and Integrated Discovery version 6.8 was used to iden-
tify for enrichment of functionally related Gene Ontology terms.
Gene expression in polarized human macrophages
Healthy human monocytes were isolated from whole blood by 
Ficoll- Paque PLUS (17144003, GE Healthcare) density centrifuga-
tion followed by magnetic selection with CD14 Human MicroBeads 
(130-050-201, Miltenyi Biotec). Monocytes were incubated for 7 days 
with RPMI 1640 (Gibco) supplemented with MCS-F (100 ng/ml) 
(300-25-100, PeproTech, UK), 10% FBS (Biowest), 1 mM glutamine 
(Invitrogen), and 1% penicillin/streptomycin (Gibco), followed by 
polarization with either LPS (100 ng/ml) (581-007-L002, Enzo Life 
Sciences, USA) and IFN- (20 ng/ml) (300-02, PeproTech, UK), 
IL-4 (20 ng/ml) (200-04, PeproTech, UK), or IL-10 (20 ng/ml) (200-
10, PeproTech, UK) for 24 hours. RNA and RT- qPCR were per-
formed, as described above using the primer sets listed in table S4.
OxLDL uptake and HDL-mediated cholesterol efflux
Assays were performed on BMDMs cultured for 5 days as described 
above. OLR1 was detected as described above. For the uptake as-
says, cells were incubated at 37°C for a further 24 hours with human 
oxLDL (5685-3557, Bio-Rad) at a concentration of 0 and 25 g/ml. 
Total cell lipids were extracted using 7:11:01 (v/v) chloroform: 
isopropanol:IGEPAL CA-630 (I8896, Sigma-Aldrich), dried at 50°C, 
and resuspended in 120 l of cholesterol assay buffer (MAK043, 
Sigma-Aldrich). Total cholesterol, free cholesterol, and cholesteryl 
esters were measured using a cholesterol quantification kit (MAK043, 
Sigma-Aldrich), according to the manufacturer’s instructions. Foam 
cells were assessed by Oil Red O [60% (v/v) in isopropanol] staining 
as described above. For the efflux assays, BMDMs were incubated 
for 24 hours in DMEM (BE12-604F, Lonza) supplemented with 0.2% 
(w/v) fatty acid–free bovine serum albumin (BSA) (A8806, Sigma- 
Aldrich) and 2.5 M TopFluor (Bodipy) cholesterol (Avanti Polar 
Lipids Inc. USA). The medium was removed, and the cells were 
washed with PBS and equilibrated for 18 hours in DMEM supple-
mented with 0.2% (w/v) fatty acid–free BSA. Efflux was measured 
after a 4-hour incubation period with human HDL (0 and 50 g/ml) 
(5685-2004, Bio-Rad). Supernatants were collected, and the cells 
were lysed with 1% (w/v) cholic acid (C1129, Sigma-Aldrich) in 
ethanol. Cholesterol efflux was calculated as the percentage of fluo-
rescence (excitation, 490 nm; emission, 520 nm) in the cell medium 
at the end of the incubation period divided by the total fluorescence 
in the medium and cells.
Statistics
All data are reported as means ± SEM unless stated otherwise in the 
figure legend. Graphs were produced and analyzed by GraphPad 
Prism software. Each data point represents a single mouse or human 
donor. For analysis of two groups, Student’s t test was performed. 
When three or more groups were compared, analysis of variance 
(ANOVA) was used, accompanied with the appropriate ad hoc 
posttest, as detailed in the specific figure legends. P values <0.05 
were considered significant.
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